表皮生长因子受体突变状态对高危I期肺腺癌患者辅助化疗的影响
本研究纳入2010至2016年间475例接受肺叶切除术的高危I期肺腺癌患者,按表皮生长因子受体突变状态分组,采用倾向性评分匹配分析辅助化疗对无复发生存的影响。结果表明,在无/未知表皮生长因子受体突变患者中辅助化疗组5年无复发生存率显著优于未化疗组(88.4%对63.6%,P=0.001),而在表皮生长因子受体突变患者中两组无显著差异(74.3%对80.5%,P=0.573)。
要点
- 高危I期肺腺癌辅助化疗的获益因表皮生长因子受体突变状态而异。
- 无/未知突变者辅助化疗5年无复发生存88.4%对未化疗63.6%,P=0.001。
- 突变者辅助化疗与未化疗5年无复发生存74.3%对80.5%,P=0.573,无显著差异。
核心结论
- 高危I期肺腺癌辅助化疗的效果因表皮生长因子受体突变状态而异,突变状态可能有助于识别可从辅助化疗中获益的患者。
研究设计与样本
- 回顾性队列研究,纳入2010至2016年间1901例病理I期(第8版)非小细胞肺癌中的475例高危(pT1c/T2a或淋巴血管浸润阳性)I期肺腺癌患者,均接受肺叶切除术,采用倾向性评分匹配调整混杂变量。
主要发现
- 在292例无/未知表皮生长因子受体突变患者中,105例(36.0%)接受辅助化疗、187例(64.0%)未接受;69对倾向性评分匹配患者中,辅助化疗组5年无复发生存率88.4%显著优于未化疗组63.6%(P=0.001)。
- 在183例表皮生长因子受体突变患者中,78例(42.6%)接受辅助化疗、105例(57.4%)未接受;49对倾向性评分匹配患者中,辅助化疗组5年无复发生存率74.3%与未化疗组80.5%无显著差异(P=0.573)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the role and effect of adjuvant chemotherapy based on epidermal growth factor receptor mutation status in patients with stage I lung adenocarcinoma. METHODS: Between 2010 and 2016, of 1901 patients with pathologic stage I (8th edition) non-small cell lung cancer, we identified 475 with high-risk (pT1c/T2a or positive for lymphovascular invasion) stage I lung adenocarcinoma who underwent lobectomy. We estimated propensity scores to adjust for confounding variables, including age, sex, Brinkman index, pulmonary functions, comorbidities, surgical approach, invasive component tumor size, visceral pleural, lymphatic, and vascular invasion, adenocarcinoma subtype, epidermal growth factor receptor mutation status, postoperative complications, and institution associated with the administration of adjuvant chemotherapy. The primary end point was recurrence-free survival. RESULTS: Of 292 patients without/unknown epidermal growth factor receptor mutation, 105 (36.0%) received adjuvant chemotherapy and 187 (64.0%) did not. In 69 pairs of patients who were propensity score matched, the 5-year recurrence-free survival was significantly better in those who underwent adjuvant chemotherapy (88.4%) than in those who did not (63.6%; P = .001). Of 183 patients with epidermal growth factor receptor mutation, 78 (42.6%) received adjuvant chemotherapy and 105 (57.4%) did not. In 49 pairs of propensity score-matched patients, there was no significant difference in the 5-year recurrence-free survival between those who underwent adjuvant chemotherapy (74.3%) and those who did not (80.5%; P = .573). CONCLUSIONS: The effect of adjuvant chemotherapy for high-risk stage I lung adenocarcinoma varied by epidermal growth factor receptor mutation status. Epidermal growth factor receptor mutation status may help to identify patients with high-risk stage I lung adenocarcinoma who may benefit from adjuvant chemotherapy.
引用
- Tsutani Y, Ito M, Shimada Y, et al. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022. PMID: 35181001. doi:10.1016/j.jtcvs.2022.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。